Sign In
Buy DXCM
$86.94
-0.370 (-0.424%)
At Close: Aug 04, 2026
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance
11:34am, Thursday, 10'th Apr 2025
DexCom says its G7 15 Day system will land on the market in the second half of 2025.
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction
10:15am, Thursday, 10'th Apr 2025
What should investors do during a market downturn? Some might resort to panic selling, but that's hardly a good strategy.
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
08:30am, Thursday, 10'th Apr 2025
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for peopl
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
09:10am, Friday, 04'th Apr 2025
DXCM continues to raise investor optimism due to its strong product portfolio.
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
08:30am, Thursday, 03'rd Apr 2025
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will ho
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
08:00am, Tuesday, 01'st Apr 2025
BURNABY, British Columbia--(BUSINESS WIRE)--The Government of Saskatchewan expands public coverage for Dexcom Continuous Glucose Monitoring Systems.
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
10:31am, Monday, 31'st Mar 2025
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
10:05am, Thursday, 27'th Mar 2025
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
08:21am, Wednesday, 26'th Mar 2025
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.
Dexcom Appoints Jon Coleman as Chief Commercial Officer
04:05pm, Tuesday, 25'th Mar 2025
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Jon Coleman as Chief Commercial Officer.
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
11:50am, Tuesday, 25'th Mar 2025
NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platfo
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
10:02am, Wednesday, 19'th Mar 2025
Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write th
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
04:00am, Wednesday, 19'th Mar 2025
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
09:11am, Friday, 14'th Mar 2025
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
History Says Shut Up And Buy: 12 Hyper-Growth Blue Chips To Buy Right Now
07:00am, Friday, 14'th Mar 2025
Market corrections, like the recent dip, are normal and temporary, with historical data showing average declines of 13-14% since 1950. Long-term investors should stay the course. Corrections often lea
